Evidence map›Paper›PMID 38169306›Full record

ArticleJournal of virology2024

Implications of the 375W mutation for HIV-1 tropism and vaccine development.

Odette Verdejo-Torres, Tania Vargas-Pavia, Syeda Fatima, Paul R Clapham, Maria J Duenas-Decamp

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Odette Verdejo-TorresProgram in Molecular Medicine, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
Tania Vargas-PaviaProgram in Molecular Medicine, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
Syeda FatimaProgram in Molecular Medicine, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
Paul R ClaphamProgram in Molecular Medicine, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
Maria J Duenas-DecampProgram in Molecular Medicine, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.ORCID 0000-0003-2020-6471
University of Massachusetts Chan Medical School · US

Funding

Identify New Determinants to Target Macrophage-Tropic Viruses and Prevent HIV-1 Brain Infection in NeuroAIDSR01MH115773 · NIMH · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI DUENAS-DECAMP, MARIA JOSE · 2018 to 2022
$2.1M
The role of the trimer association domain (TAD) in controlling the conformation of the HIV-1 envelope trimer and protection of the CD4 binding siteR21AI127231 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI DUENAS-DECAMP, MARIA JOSE · 2016 to 2017
$461k
NIAID NIH HHS R21 AI127231NIMH NIH HHS R01 MH115773
6 · The paper itself

Abstract

Understanding how different amino acids affect the HIV-1 envelope (Env) trimer will greatly help the design and development of vaccines that induce broadly neutralizing antibodies (bnAbs). A tryptophan residue at position 375 that opens the CD4 binding site without modifying the trimer apex was identified using our saturation mutagenesis strategy. 375W was introduced into a large panel of 27 transmitted/founder, acute stage, chronic infection, and AIDS macrophage-tropic and non-macrophage-tropic primary envelopes from different clades (A, B, C, D, and G) as well as complex and circulating recombinants. We evaluated soluble CD4 and monoclonal antibody neutralization of WT and mutant Envs together with macrophage infection. The 375W substitution increased sensitivity to soluble CD4 in all 27 Envs and macrophage infection in many Envs including an X4 variant. Importantly, 375W did not impair or abrogate neutralization by potent bnAbs. Variants that were already highly macrophage tropic were compromised for macrophage tropism, indicating that other structural factors are involved. Of note, we observed a macrophage-tropic (clade G) and intermediate macrophage-tropic (clades C and D) primary Envs from the blood and not from the central nervous system (CNS), indicating that such variants could be released from the brain or evolve outside the CNS. Our data also indicate that "intermediate" macrophage-tropic variants should belong to a new class of HIV-1 tropism. These Envs infected macrophages more efficiently than non-macrophage-tropic variants without reaching the high levels of macrophage-tropic brain variants. In summary, we show that 375W is ideal for inclusion into HIV-1 vaccines, increasing Env binding to CD4 for widely diverse Envs from different clades and disease stages.IMPORTANCESubstitutions exposing the CD4 binding site (CD4bs) on HIV-1 trimers but still occluding non-neutralizing, immunogenic epitopes are desirable to develop HIV-1 vaccines. If such substitutions induce similar structural changes in trimers across diverse clades, they could be exploited for the development of multi-clade envelope (Env) vaccines. We show that the 375W substitution increases CD4 affinity for envelopes of all clades, circulating recombinant forms, and complex Envs tested, independent of disease stage. Clade B and C Envs with an exposed CD4bs were described for macrophage-tropic strains from the central nervous system (CNS). Here, we show that intermediate (clades C and D) and macrophage-tropic (clade G) envelopes can be detected outside the CNS. Vaccines targeting the CD4bs will be particularly effective against such strains and CNS disease.

Indexed as

env Gene Products, Human Immunodeficiency VirusHIV-1HIV InfectionsViral TropismBroadly Neutralizing AntibodiesCD4 AntigensHIV AntibodiesHumansMacrophagesMutationVaccine DevelopmentBroadly Neutralizing AntibodiesCD4 Antigensenv Gene Products, Human Immunodeficiency VirusHIV AntibodiesenvelopeHIV-1neutralizationtropismvaccines

Identifiers

PMID38169306
PMCPMC10804988
OpenAlexW4390545272

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.